JNJ 38877618Alternative Names: JNJ-38877618
Latest Information Update: 21 Mar 2016
At a glance
- Originator Janssen-Cilag
- Mechanism of Action Proto oncogene protein c met inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 15 Oct 2013 Janssen-Cilag plans a phase I trial for Healthy volunteers in the UK (NCT01964872)